Read this topic

A fresh doctor could memorise "SSRIs increase serotonin" without ever knowing what that sentence actually means at a cellular level. Every psychiatric drug works by nudging one or more steps of SYNAPTIC NEUROTRANSMISSION (the process by which one neuron sends a chemical signal to the next across a synapse), so understanding the steps in order is what turns a memorised drug list into something you can reason about. Hold the phrase STEP IN THE CHAIN through every section below, because each drug class targets one specific step, not the process as a whole.

A SYNAPSE is the small gap between two neurons, the PRESYNAPTIC neuron (the one sending the signal) and the POSTSYNAPTIC neuron (the one receiving it), across which a chemical messenger, the NEUROTRANSMITTER, carries information. Synaptic neurotransmission is the sequence of events that converts an electrical signal in the presynaptic neuron into a chemical signal crossing the gap, and then back into an electrical or biochemical effect in the postsynaptic neuron.

A common mistake is assuming every psychiatric drug increases a neurotransmitter's release. Most instead act at step four or step five: blocking a receptor (antipsychotics blocking dopamine D2 receptors), blocking reuptake (SSRIs, SNRIs, TCAs), or inhibiting a degrading enzyme (MAO inhibitors): rather than directly forcing more vesicle release at step three. Naming the correct step, not just the correct neurotransmitter, is usually what an exam question is really testing.

Every act of chemical neurotransmission follows the same fixed sequence, regardless of which neurotransmitter is involved: an electrical signal arrives, it triggers a chemical entry signal, that signal causes release, the released chemical binds a receptor, and the signal is then terminated so the synapse can reset. Learning these five steps in order, rather than memorising isolated drug facts, is what makes the rest of psychopharmacology fall into place, because nearly every drug class can be located at exactly one step.

The process starts when an ACTION POTENTIAL (a brief electrical impulse travelling along the neuron's axon) reaches the presynaptic terminal, the specialised swelling at the axon's end that faces the synapse. Imagine an electrical pulse racing down a long wire and arriving at a junction box: the action potential is that pulse, and the presynaptic terminal is the junction box where the electrical signal must now be converted into something that can cross a physical gap.

Arrival of the action potential opens VOLTAGE-GATED CALCIUM CHANNELS (channels in the membrane that open in response to the electrical change) in the presynaptic terminal, allowing calcium ions (Ca2+) to flow in from outside the cell, where their concentration is normally much higher. This calcium influx is the trigger step: without it, the next stage cannot occur, which is exactly why some drugs and toxins that block these channels can silence neurotransmission entirely.

The rise in intracellular calcium causes small membrane-bound sacs called SYNAPTIC VESICLES (pre-packaged stores of neurotransmitter molecules) to fuse with the presynaptic membrane and release their contents into the synaptic cleft (the gap between the two neurons) by exocytosis. This is the step that physically delivers the neurotransmitter into the space where it can reach the postsynaptic cell.

The released neurotransmitter diffuses across the synaptic cleft and binds to specific RECEPTORS (protein structures on the postsynaptic membrane shaped to recognise that particular neurotransmitter). Binding can open an ion channel directly (an ionotropic receptor, producing a fast electrical effect) or trigger a slower intracellular signalling cascade (a metabotropic receptor, often via a G-protein). The type of receptor activated, not just which neurotransmitter is released, determines the ultimate effect on the postsynaptic neuron.

For a synapse to be usable again, the neurotransmitter's action must end. This happens through REUPTAKE (transporter proteins pump the neurotransmitter back into the presynaptic neuron for recycling: the step SSRIs and SNRIs target by blocking the serotonin or noradrenaline transporter) or through ENZYMATIC DEGRADATION (an enzyme breaks the neurotransmitter down in the cleft, as monoamine oxidase does to dopamine, noradrenaline, and serotonin, and as acetylcholinesterase does to acetylcholine). Consider a tap left running: reuptake is like a drain removing water as fast as it arrives, and blocking that drain (as an SSRI does) leaves more water, more neurotransmitter, in the sink for longer.

Chemical synaptic transmission (everything above) is often confused with electrical synapses (gap junctions: direct, near-instant ion flow between two neurons through connecting channel proteins, with no neurotransmitter, no synaptic cleft, and no receptor step at all): electrical synapses are rare in the mammalian brain, mostly linking certain interneurons for rapid synchronised firing, and no psychiatric drug acts on them. Neurotransmission is also confused with neuromodulation (a slower, more diffuse chemical influence, such as widespread serotonergic or noradrenergic tone, that adjusts the sensitivity of many synapses at once rather than transmitting one discrete point-to-point signal). An ionotropic receptor effect (fast, direct, milliseconds) should not be confused with a metabotropic receptor effect (slower, cascade-based, seconds to longer), even though both are triggered by the same step-four binding event.

This is a mechanism, not a disorder, so there is no diagnostic criterion to apply: instead, researchers and clinicians identify which step is involved using specific techniques. Electrophysiology measures postsynaptic electrical responses directly. Microdialysis samples neurotransmitter concentration in the synaptic cleft over time. PET imaging with radioligands can visualise receptor binding in a living brain: for example, dopamine D2 receptor occupancy studies are how researchers established that antipsychotics typically need to occupy a substantial majority of D2 receptors to produce an antipsychotic effect, directly linking step four (receptor binding) to clinical response.

Mapping a drug class onto its step clarifies both mechanism and side-effect profile, and clinicians use this reasoning directly when choosing or switching treatment: SSRIs act at the reuptake step for serotonin, MAO inhibitors act at the degradation step for monoamines generally (which is why they carry dietary tyramine restrictions and interaction risks, per Maudsley Prescribing Guidelines), and antipsychotics act at the receptor-binding step, mainly blocking dopamine D2 receptors. Switching a non-responder from a reuptake-step drug (an SSRI) to a degradation-step drug (an MAOI), a recognised augmentation strategy in Maudsley-guided prescribing, is a direct clinical application of targeting a different point in the same chain rather than simply trying "a stronger dose" of the same mechanism.

Questions often describe a drug's effect (for example, prolonged neurotransmitter presence in the synapse) and expect the candidate to identify WHICH step is blocked, reuptake versus enzymatic breakdown, rather than answering with the neurotransmitter's name alone. Another trap conflates the trigger step (calcium influx) with the release step (vesicle fusion), when they are sequential and distinct events in the same short chain.

Synaptic neurotransmission is a fixed five-step chain (action potential, calcium influx, vesicle release, receptor binding, termination) and nearly every psychiatric drug can be located at exactly one or two of those steps, which is why learning the sequence in order makes pharmacology far easier to reason through than memorising isolated facts.